INmune Bio (INMB) Reports Data on Combination Therapy with INB03 on Overcoming Resistance to HER2 Targeted Therapies in Breast Cancer - StreetInsider.com

6/16/2022 12:00:00 AM3 years 8 months ago

...

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premiumhere. INmune Bio, Inc. (NASDAQ: INMB) (the âCompanyâ), a clinical-stage immunology compan… [+2894 chars]

full article...